Comparative Pharmacology
Head-to-head clinical analysis: IMPOYZ versus SELARSDI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IMPOYZ versus SELARSDI.
IMPOYZ vs SELARSDI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
IMPOYZ is a monoclonal antibody that binds to and inhibits the activity of interleukin-23 (IL-23), a cytokine involved in inflammatory and immune responses. By blocking IL-23, it reduces the production of pro-inflammatory cytokines and attenuates the inflammatory cascade.
Selective angiotensin II type 1 receptor antagonist that blocks vasoconstriction and aldosterone secretion.
100 mg orally twice daily
Intravenous 0.15 mg/kg every 8 hours for 14 days.
None Documented
None Documented
Terminal elimination half-life 6–8 hours in adults with normal renal function; prolonged to 15–30 hours in severe renal impairment (CrCl <30 mL/min).
Terminal elimination half-life is approximately 11 hours (range 7–15 hours), supporting twice-daily dosing; half-life may be prolonged in renal impairment.
Primarily renal (70–80% as unchanged drug via glomerular filtration and tubular secretion); biliary/fecal (15–20%) with minor hepatic metabolism.
Primarily renal excretion of unchanged drug (approximately 70%) and glucuronide conjugate (approximately 20%); biliary/fecal elimination accounts for less than 10%.
Category C
Category C
Unknown
Unknown